

**FORMULATION AND EVALUATION OF FLOATING MICROSPHERES OF METFORMIN HYDROCHLORIDE**

**Naga Sai Syamala Puvvula<sup>2\*</sup>, Medara Prasad<sup>1</sup>, Surendranath Betala<sup>2</sup>,  
M. Mohan Varma<sup>3</sup> and K. Abbulu<sup>4</sup>**

<sup>2</sup>Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, West Godavari, A.P.

<sup>1</sup>Hetero Drugs Limited, Hyderabad, Telangana.

<sup>3</sup>Sri Vishnu College of Pharmacy, Bhimavaram, West Godavari, A.P.

<sup>4</sup>Nova Institute of Pharmaceutical Education and Research, Jafferghuda, Hyderabad, Telangana.

Naga Sai Syamala Puvvula.

Article Received on  
15 May 2016,

Revised on 05 June 2016,  
Accepted on 26 June 2016

DOI: 10.20959/wjpr20167-6276

**\*Corresponding Author**

**Naga Sai Syamala Puvvula**

Sri Vasavi Institute of  
Pharmaceutical Sciences,  
Tadepalligudem, West  
Godavari, A.P.

**ABSTRACT**

Metformin Hydrochloride is a hypoglycemic agent used in the treatment of non-insulin dependent Diabetes mellitus. It is a BCS Class –III drug having poor permeability. Plasma half life ranges from 1.5-3 hrs & oral bioavailability is 50-60%. Hence require frequent oral administration for adequate treatment of Diabetes in order to extend the gastric retention time oral sustained dosage form was developed in the form of microspheres using polymers (sodium CMC, HPMC K 100 M). The results presented that drug dissolution rate and drug entrapment increases while decreasing the polymer amount. All the formulations are evaluated for dissolution, entrapment efficiency,

percentage buoyancy and Metformin Hydrochloride Microspheres of formulations, F-4 was found to be optimized formulation based on in-vitro release pattern and percentage buoyancy entrapment efficiency.

**KEYWORDS:** Metformin Hydrochloride half life formulations, efficiency.

**INTRODUCTION**

Oral delivery of drugs<sup>[1]</sup> is the most preferable route of drug delivery due to ease of administration, patient compliance and flexibility in formulation etc. various attempts have been made to prolong the retention time of the dosage form in the stomach.

The present study involved, preparation of Metformin Hydrochloride floating microspheres to improve the bioavailability by increasing residence time in stomach. Metformin is an anti-hyperglycemic agent which improves glucose tolerance in patients with type-2 diabetes. Its pharmacologic mechanisms of action are different from other classes of oral anti-hyperglycemic agents. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. Metformin Hydrochloride quite frequently causes gastrointestinal problems such as nausea, stomach pain, diarrhea. It has short half life (4-6 hrs) and is absorbed from upper intestine with in 6 hrs. So repeated administration required is to maintain effective plasma concentration. So our objective is to prepare a sustained release floating microspheres. Thus, the development of floating drug delivery systems would clearly be advantageous. Dosage forms that are retained in the stomach would increase the absorption, improve drug efficiency, and decrease dose requirements. Thus an attempt was made in this investigation to use HPMC K100M, sodium CMC polymers to prepare Metformin Hydrochloride floating Microspheres.

### **Floating microsphere drug delivery system**

In floating types the bulk density is less than the gastric fluid and so remains buoyant in stomach without affecting gastric emptying rate. The drug is released slowly at the desired rate, if the system is floating on gastric content, increases gastric residence and fluctuation in plasma concentration. It also reduces chances of striking and dose dumping and produce prolonged therapeutic effect.

### **Process of Formulation**

Floating alginate microspheres of Metformin hydrochloride were prepared by ionotropic gelation technique using different proportion of polymers as shown in table No. 3. A 3% w/v solution of sodium alginate solution was added to weighed amount of Na CMC dissolved in required quantity of ethanol. Weighed quantity of drug and HPMC K100 M was triturated to form fine powder, and then added to above solution. Sodium carbonate, gas forming agent was added to this mixture.

### **Agitation**

The above mixture was taken into beaker for which an agitator and the agitator is allowed to rotate at fixed speed. Now the above solution of drug and polymer was dropped into 100 ml of gently agitated calcium chloride (3 % w/v) solution using a 26 G syringe needle to obtain

microspheres. The solution containing Microspheres was stirred slowly using magnetic bead for about 10 min. the Microspheres were further allowed to remain in the same solution for 20 min to improve mechanical strength.

### **Filtration**

The formed Microspheres were filtered, by using whatmann filter paper and washed with distilled water, air-dried at room temperature and stored in desiccators.

### **Drying**

After filtration microspheres were dried in the hot air oven at the temperature 35-45<sup>0</sup>C for the period of 1- 2 hrs. Then the microspheres kept in desiccators.

### **Buoyancy Nature**

Alginate microspheres were formed as alginate undergoes ionotropic gelation by calcium ions and carbon dioxide develops from the reaction of bicarbonate salt with acid which permeates through alginate matrix leaving gas bubbles or pores within microspheres, providing the buoyancy.

## **MATERIALS AND METHODS**

Metformin hydrochloride was purchased from Yarrow chem. Products Mumbai, India, Hydroxyl propyl methyl cellulose was purchased from K100M Ozone International Mumbai. Sodium Carboxy methyl cellulose was purchased from Ozone International Mumbai, Sodium bicarbonate and Calcium chloride was purchased from S.D. Fine chemicals, Ltd, Mumbai. Sodium alginate was purchased from Loba Chemie Pvt. Ltd. Mumbai.


The FT-IR spectra of pure Metformin Hydrochloride and microspheres loaded with Metformin Hydrochloride were recorded to check drug polymer interaction and stability of drug.

## **RESULTS AND DISCUSSIONS**

### **Calibration curve of Metformin Hydrochloride by UV spectral analysis**

Accurately weighed amount of Metformin Hydrochloride (100mg) was dissolved in p<sup>H</sup> 1.2 buffer to form a clear solution and it was made up to the volume in 100 ml volumetric flask with p<sup>H</sup> 1.2 HCL buffer. From this solution 1ml was transferred into 10 ml of volumetric flask and it was made upto volume with HCL buffer pH 1.2. The resulting solution (100 µg/ml). From this 1ml, 2ml, 3ml, 4ml, 5ml was pipetted out and diluted to 10 ml with pH 1.2

HCL to obtain 10ug/ml, 20ug/ml, 30ug/ml, 40ug/ml, 50ug/ml and scanned over the range 233 nm against pH 1.2 HCl buffer as blank UV spectrophotometer.



**Fig No.5: Calibration curve for Metformin Hydrochloride in pH 1.2HCl buffer**


### Preformulation Studies

#### Drug Excipient compatibility studies


The compatibility of drug and formulation components is important prerequisite before formulation. It is therefore necessary to confirm that the drug does not react with the polymers and excipients under experimental conditions and affect the shelf life of product or any other unwanted effects on the formulation.

#### Fourier transforms infra-red spectroscopy (FT-IR) analysis


The compatibility study between the drug and the polymer was done by I.R studies. No major peak shift was observed in the I.R graphs in major functional groups. Based on the compatibility studies obtained by I.R studies, the polymer HPMC K100 M, sodium CMC were taken for the optimization of the formulation, which is compatible with the drug. The FT-IR spectra of pure Metformin Hydrochloride and microspheres loaded with Metformin Hydrochloride were recorded to check drug polymer interaction and stability of drug.



**Fig No. 1: FTIR graph for the pure drug Metformin Hydrochloride**



**Fig No. 2: FTIR graph of  
Drug and polymer (Na CMC)**




**Fig No: 3 FTIR graph of Drug and  
Polymer (HPMC K 100 M)**

### Evaluation of prepared microspheres

#### External morphological study

##### Particle size

External morphology of microspheres was determined using scanning electron microscopy (SEM). Samples were diluted with ultra-purified water to obtain a suitable concentration. Then the samples were spread on a sample holder and dried using vacuum and examined by a scanning electron microscopy.



**Fig No: 4 SEM of formulated Microspheres**

##### Percentage yield

The prepared microspheres of all batches were accurately weighed. The measured weight of prepared microspheres was divided by total amount of all the excipient and drug used in

preparation of the microspheres, which give the total percentage yield of floating microspheres.

It was calculated by using following equation.

$$PY(\%) = \frac{\text{Actual weight of product}}{\text{Total weight of excipient and drug}}$$

**Table No1: Percentage yield of different formulations**

Formulations	Total weight taken (mg)	Total weight of microspheres (mg)	Percentage yield (%)
F-1	1100	750	68.1
F-2	1050	700	66.6
F-3	1050	750	71.4
F-4	1000	720	72

### Inference

From the above table the percentage yield of prepared Microspheres was found to be more for the formulation F- 4 (72%).

### Drug content/entrapment efficiency

100 mg of prepared floating microspheres are dispersed in 100ml of pH1.2 HCL buffer. This dispersion kept a side overnight. Then samples were taken from this solution and absorbance values measured by UV spectrophotometer at 233 nm. By using drug content values we can measure the entrapment efficiency.

$$\text{Microencapsulation efficiency} = \frac{\text{Estimated percent drug content}}{\text{Theoretical percent drug content}} \times 100$$

In calculation of entrapment efficiency first measure amount of drug loaded in the total microspheres. For this U.V visible spectrophotometer is used for the analysis of drug.

**Table No. 2: Entrapment efficiency of the different formulations**

Formulations	Observed drug (mg)	Total amount taken (mg)	Entrapment efficiency(%)
F-1	45	100	67.5
F-2	47	100	65.8
F-3	46	100	69
F-4	49	100	70.56

### Inference

From the above table Entrapment efficiency was found to be more for the formulation F – 4 i.e. (70.56%).

### Percentage buoyancy

Microspheres (0.3g) were spread over the surface of a USP XXIV dissolution apparatus (type II) filed with 900 ml 0.1 N HCL. The medium was agitated with paddle rotating at 100 rpm for 12 hrs. The floating and the settled portion of microspheres were recovered separately. The Microspheres were dried and weighed. Buoyancy percentage was calculated as the ratio of the microspheres that remained floating and the total mass of the Microspheres.

$$\% \text{ Floating microspheres} = \frac{\text{Weight of floating microspheres at time } t}{\text{Initial weight of microspheres}} \times 100$$

**Table No. 3: Buoyancy percentage of different formulations**

Formulation code	Percentage buoyancy
F-1	81.66
F-2	83.33
F-3	85.1
F-4	86

### Inference

From the above table the percentage buoyancy was found to be more for the formulation F -4.


## IN VITRO DISSOLUTION DATA

### Dissolution test

The dissolution profiles of floating microspheres of Metformin Hydrochloride were investigated with a dissolution apparatus (LAB INDIA DS-8000), according to type II paddle method, with the rotation speed of paddle was set on 100 and the bath temperature was kept at  $37.0 \pm 0.5^{\circ}\text{C}$ . Equivalent 100 percent of drug preparation was filled into the empty capsule. The capsule was put into the vessel containing 900 ml of  $\text{p}^{\text{H}}$  1.2 HCl. To avoid the float of capsule sinkers were used. At specific intervals, 1 ml of aliquot of dissolution medium was sampled, filtered the sample by the U.V and visible spectrophotometer. Absorbance of the sample solution compared with the standard solution having a known concentration of Metformin Hydrochloride was drawn at 233 nm.

**Table No.16: Comparative dissolution profile for formulation F1 – F4**

S.NO	F-1 % CDR	F-2 % CDR	F-3 % CDR	F-4 % CDR
1	0	0	0	0
2	11.08	12.1	19.9	9.5
3	18	21.6	21.6	26.1
4	27	26.1	31.5	29.7
5	31.5	37.8	39.6	41.4
6	37.8	45	46.8	47.7
7	46.8	50.4	54	57.6
8	52.2	59.4	71.1	67.5
9	56.7	69.3	75.6	81
10	67.5	71.1	79.2	82.8
11	73.8	74.7	82.8	84.6
12	75.6	80.1	85.5	87.3
13	81	81	88.2	90

**Fig No. 20: Comparative dissolution profile for formulation F1-F4.****Inference**



From the above fig the dissolution profile for the formulation F-4 was found to be have the more cumulative % drug release.

**DISSOLUTION – APPLICATION OF KINETICS OF F-4****Table NO. 17: Application of kinetics for dissolution profile of formulation F-4.**



S.NO	TIME	% CDR	Log % CDR	Log % drug unreleased	Square root time	Log time
1	0.5	9.5	0.9777	1.9566	0.7071	-0.301
2	1	26.1	1.4166	1.8686	1	0
3	2	29.7	1.4727	1.8469	1.414	0.3010
4	3	41.4	1.6170	1.7678	1.732	0.4771
5	4	47.7	1.6785	1.7185	2	0.602
6	5	57.6	1.7604	1.6273	2.236	0.6989
7	6	67.5	1.8293	1.5118	2.449	0.778



8	7	81.0	1.9084	1.2787	2.645	0.845
9	8	82.8	1.9180	1.2355	2.828	0.903
10	9	84.6	1.9273	1.1875	3	0.954
11	10	87.3	1.9410	1.1038	3.167	1
12	11	90	1.9542	1	3.316	1.041

**ZERO ORDER PLOT****Fig No. 21: Zero order plot for optimized formulation F-4****FIRST ORDER PLOT****Fig No. 22: First Order Plot for optimized formulation F-4****Inference**

From the above graphs the  $R^2$  value is (0.977) and for zero order plot  $R^2$  value is (0.957) which indicating that the order of release was first order.

**HIGUCHI'S PLOT****Fig No. 23: Higuchi's plot for optimized formulation F-4****KORSEMEYER- PEPPAS PLOT****Fig No. 24: Korsmeyer -Peppas plot for optimized formulation F-4****Inference**

As per the above plot Fig No. 17 and Fig No. 18. The  $R^2$  value for Higuchi (0.974) and for Korsmeyer - Peppas plot (0.964), showing that the mechanism of drug release from the formulation was found to be Diffusion controlled release.

**Stability studies**

The accelerated stability study for the formulation at  $40 \pm 2^\circ\text{C}$  and  $75 \pm 5\%$  RH was conducted for the 3 months, which includes the testing of parameters like identification of physical characters, identified by IR studies, dissolution profile and assay throughout period.

The stability studies on optimized formulation of Metformin Hydrochloride floating Microspheres were conducted according to the ICH guidelines.

## CONCLUSION

The present study involved, preparation of Metformin Hydrochloride floating microspheres to improve the bioavailability by increasing residence time in stomach. Thus an attempt was made in this investigation to use HPMC K100M, sodium CMC polymers to prepare Metformin Hydrochloride floating Microspheres.

From the study, it was concluded that spherical and free flowing Microspheres of Metformin HCL could be successfully prepared by Ionotropic gelation technique with high entrapment efficiency and prolonged release characteristics.

### It was concluded that

- Compatibility studies revealed no interactions between the drug and polymers used.
- Formulated Microspheres gave satisfactory result for various physic- chemical evaluations like physical appearance, surface morphology, entrapment efficiency, percentage drug loading, percentage buoyancy and In-vitro drug release.
- The prepared beads showed required drug release in about 12 hours as aimed for.
- From the research, it can be concluded that Metformin Hydrochloride can be formulated as Microspheres for the desired use in treatment of Diabetes Mellitus.

## REFERENCES

1. Chein Y.W, Novel Drug Delivery System: Fundamentals and applications, 2<sup>nd</sup> ed: Marcel Dekker; New York, 1992; 4-56.
2. J.P, Soarse, J.E. Santos, J.O. Chierce and E.T.G Cavatheiro, Thermal behaviour of alginic acid and its sodium salt, ECL. Quimsao Paulo, 2004; 29: 53-56.
3. Desai S, Bolton S. A Floating Controlled Release system: In-vitro and In-vivo evaluation, J. Pharm Res., 1986; 3: 208 -213.
4. Leon Lachman, Herbet A. Lieberman, Joseph L. Kanig, "The Theory and Practice of Industrial Pharmacy", Varghese Publishing house, Third Edition, 101-104.
5. Patel H, Patel R, Patel G. Ionotropic Gelation Technique for Microencapsulation of Antihypertensive drug. Webmed Central pharmaceutical sciences, 2010; 1(10).
6. A.V. Yadav H. mote, Development of Biodegradable starch for Intranasal Delivery, Indian Journal of Pharmaceutical Sciences, 2008; 70(2): 170-174.

7. Ghodake J.D, Vidhate J.S, Shinde D.A, Kadam A.N. "Formulation of Floating Microsphere containing Anti-diabetic Drug". International Journal of Pharm Tech, 2010; 2(1): 378-384.
8. Sreenivasulu.S, Harish Nayari M, Brijesh Yadav, Narayana Charyulu R, Satyanarayana D, and Subramanayam E.V.S. Formulation and in vitro evaluation of gastric oral floating Microspheres of Metformin Hcl. Indian j. pharm. Educ. Res., 2008; 42(2): 174-183.
9. Vinod KR, Sri AP, Banji D, Anbazhagan S, Vasa S, Sandhya S. Formulation and in vitro characterization of lansoprazole floating gastroretentive microspheres by modified non aqueous solvent evaporation method. Der Pharm. Chemica, 2010; 2(5): 419-425.
10. Manish Patel P, Patel MM, Patel KN, Patel DR, Patel UL. Designing and evaluation of microspheres of verapamil hydrochloride, effect of methocel. Research journal of pharmaceutical dosage forms and technology, 2009; 1: 22-28.
11. Gattani Y.S., Floating Multiparticulate drug delivery systems: an overview, International Journal of Pharma and Bio Sciences, 2010; 2.
12. Tanwar YS, Naruka PS, Ojha GR. Development and evaluation of floating microspheres of verapamil hydrochloride. Brazilian Journal of Pharm. Sci., 2007; 43(4): 529-534.
13. Jain AK, Jain CP. Buoyant microspheres of Famotidine: An Approachable Dosage form for Gastric treatment. J. Young Pharm, Dec, 2009; 1(1): 20-23.
14. Senthilkumar SK, Jaykar B, Kavimani S. Formulation, Characterization and Invitro evaluation of floating microsphere containing Rabeprazole sodium. JITPS, 2010; 1(6): 274-282.
15. Karthikeyan D, Karthikeyan M, Ramasamy C. Development of floating microspheres to improve oral bioavailability of cefpodoxime proxetil. Acta Pharm. Scientia, 2010; 52: 101-104.
16. Ghodake. P, Patil Sangamesh A, Belhekar Anaga A, Halligudi Shivraj B, Aminabhavi Tejraj M. preparation and evaluation of floating microspheres with Metformin Hydrochloride. Journal of pharmacy Research, 2007; 105: 2764-2771.
17. Srivastava AK, Ridhurkar DN, Wadhwa S. Floating microspheres of cimetidine: Formulation, and characterization and in vitro evaluation. Acta Pharm, 2005; 55: 277-285.
18. Kale RD and Tayade PT. a multiple unit floating drug delivery system of piroxicam using Eudragit, HPMC, EC polymers Indian Journal of Pharmaceutical Sciences, 2007; 69: 120-123.

19. Shashikant Barhate D, Yogesh Rupnar S, Rupesh Sonvane M and Rahulkumar Rahane D. Formulation and evaluation of floating microspheres of Ketorolac Trometamol. International Journal of Pharma Research and Development, 2009; 1: 1-8.
20. Yuveraj Singh Tanwar, Pushpendra singh Naruka, Garima Rani Ojha Development and evaluation of floating microspheres of Verapamil hydrochloride. Brazilian Journal of Pharmaceutical Sciences, 2007; 4: 529-534.
21. Narasaiah, Pasha ST, srinivasan S, Ray S. Design and Optimization of a Multiparticulate Gastroretentive Dosage Form Sumanatriptan Succinate floating tablets. Journal of Pharmaceutical Science and Technology, 2009; 1: 40-47.
22. Rokhade Ajit P, Patil Sangamesh A, Belhekar Anaga A, Halligudi Shivraj B, Aminabhavi Tejraj M. preparation and evaluation of cellulose acetate butyrate and poly (ethylene oxide) blend microspheres for gastroretentive floating delivery of Repaglinide. Journal of Applied Polymer science, 2007; 105: 2764-2771.
23. Danbrow M, Samuelov Y, Zero order drug delivery from double – layered porous films: release rate profiles from ethyl cellulose, Hydroxypropyl cellulose and Polyethylene glycol mixtures, Journal of Pharmacy and Pharmacology, 1980; 463–470.